What is Epithalon (Epitalon)?

Epithalon, also written Epitalon or Epithalone, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG) [6]. It is a short, four-residue peptide, not a hormone, antibody or small-molecule drug, and it is supplied as a research reagent rather than a therapeutic product. The published literature describes it as synthesised on the basis of the amino-acid composition of Epithalamin, a bovine pineal gland extract, and later identified in pineal gland polypeptide complex solution [6]. The two preparations are chemically distinct and their evidence should not be treated as interchangeable [7].

The mechanistic work on this compound centres on telomerase and telomere maintenance, specifically the induction of telomerase enzyme activity and upregulation of human telomerase reverse transcriptase (hTERT), with alternative lengthening of telomeres (ALT) activity also reported in some cell models [4][5].

Research Studies

Epithalon and telomere length in human cell lines

The most directly relevant in vitro work examined whether Epitalon increases telomere length in human cell lines and by which route. The authors state that Epitalon is a naturally occurring tetrapeptide known for anti-aging effects on mammalian cells, acting through induction of telomerase enzyme activity and consequent extension of telomere length [4]. They note that telomere length is considered a biomarker of aging and that maintaining or increasing it may contribute to healthy aging and longevity [4].

The same paper is explicit about the gap it addresses: although Epitalon had been the subject of several anti-aging studies, quantitative data on the biomolecular pathway leading to telomere length increase, hTERT mRNA expression, telomerase enzyme activity and ALT activation had not been extensive [4][5]. The reported finding is that telomere length increased in human cell lines through telomerase upregulation or ALT activity [4][5]. A correction to this work has also been published [3].

Epithalon and geroprotective and neuroendocrine effects

A review covering roughly 25 years of work on the compound reports that it has been studied using in vitro, in vivo and in silico methods, and that results indicate significant geroprotective and neuroendocrine effects [6]. Those effects are attributed to antioxidant, neuroprotective and antimutagenic activity, arising from both specific and nonspecific mechanisms [6]. This is a review-level summary rather than a single controlled experiment, and the underlying studies span multiple model systems.

Epithalon and hTERT activation in preclinical models

Preclinical evidence summarised in the regenerative and longevity literature suggests that Epitalon may activate telomerase by upregulating hTERT [8]. The same source reports work in aged primates [8]. These are preclinical findings; they are not human clinical endpoint data, and the primate work is described at the level of a review rather than as a primary report on this page.

Epithalon and delayed wound healing in a diabetic retinopathy model

An in vitro study tested the hypothesis that the antioxidant tetrapeptide Epitalon enhances delayed wound healing in a model of diabetic retinopathy [10]. Diabetic retinopathy is described as the most common complication of diabetes mellitus and a leading cause of vision loss, and short peptides including di-, tri- and tetrapeptides are noted to have antioxidant, antimicrobial and anti-inflammatory activities [10]. This is an in vitro model, not a clinical trial, and the finding should be read as a cell-culture observation.

Epithalon and the therapeutic peptide context in gerontology

A narrative review of therapeutic peptides in gerontology places compounds of this class against fundamental hallmarks of aging, including metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [2]. The review covers mechanisms, clinical applications, evidence base and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus and regulatory databases [2]. Epithalon appears within this broader class discussion rather than as the review's sole subject.

Epithalon and peptide signalling pathways in tissue regeneration

In the orthopaedic peptide literature, therapeutic peptides are described as acting on pathways such as PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, with influence over tissue regeneration [9]. This is a class-level statement about peptide signalling, not a finding specific to Epithalon, and it is included here only to indicate the pathway families against which short peptides are studied.

Epithalon and the distinction from Epithalamin

A narrative review of Epitalon and Epithalamin in regenerative and longevity medicine states that Epitalon is a synthetic tetrapeptide developed from the amino-acid composition of epithalamin, a pineal-derived polypeptide preparation, and that although the two are historically related they are chemically distinct, with evidence that should not be considered interchangeable [7]. This distinction matters when reading older literature, where the two names are sometimes used loosely.

Epithalon and cellular senescence markers in resistant cell models

Work on multidrug-resistant natural killer/T-cell lymphoma models established with adriamycin confirmed cellular senescence using markers including P16, P21 and senescence-associated β-galactosidase, and identified LCP2 as a key protein through proteomic sequencing of plasma from clinical patients and resistant cells [1]. This study is not an Epithalon study; it is included because senescence markers and resistance mechanisms are the context in which geroprotective and antimutagenic claims about short peptides are typically framed [1][6].

What the evidence does and does not show

• In vitro: telomere length increase in human cell lines via telomerase upregulation or ALT activity [4][5].
• Preclinical: suggested hTERT upregulation and telomerase activation, including work in aged primates [8].
• Review-level: geroprotective, neuroendocrine, antioxidant, neuroprotective and antimutagenic effects across in vitro, in vivo and in silico studies [6].
• Model-level: enhanced delayed wound healing in an in vitro diabetic retinopathy model [10].
• Not established here: human clinical endpoint data. No claim on this page should be read as a demonstrated human outcome.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for personal use.

Sources

• [1] LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma. https://europepmc.org/article/PMC/PMC13408427
• [2] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. https://europepmc.org/article/PMC/PMC13095733
• [3] Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. https://europepmc.org/article/PMC/PMC12619744
• [4] Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. https://europepmc.org/article/PMC/PMC12411320
• [5] Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. https://doi.org/10.21203/rs.3.rs-7066545/v1
• [6] Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. https://europepmc.org/article/PMC/PMC11943447
• [7] Epitalon and Epithalamin in Regenerative and Longevity Medicine: Mechanisms, Evidence, and Translational Gaps. https://doi.org/10.20944/preprints202609.0801.v1
• [8] From Cellular Aging to Tissue Protection: Epitalon in Regenerative and Longevity Medicine. https://doi.org/10.20944/preprints202607.2123.v1
• [9] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://europepmc.org/article/PMC/PMC12753158
• [10] The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. https://europepmc.org/article/PMC/PMC12356729